OABI - OmniAb Inc Volatility & Greeks
This article provides a detailed financial overview of OmniAb Inc (OABI), including its stock performance metrics, volatility, and various financial ratios. It lists key data such as market capitalization, income, sales, and per-share values, alongside insider ownership, institutional ownership, and analyst recommendations. The report also highlights recent earnings surprises and stock performance across different timeframes.
OmniAb (OABI) Gains More Than 38% Over 6 Months, Can It Go Higher?
OmniAb, Inc. (NASDAQ: OABI) has seen significant gains, rising over 38% in the past six months and 74% since its Q1 2026 earnings release. The company's revenue surged from $4.2 million to $14.4 million in Q1 2026, driven by milestone payments, while R&D and G&A costs decreased, leading to a narrower net loss. Consequently, OmniAb has raised its full-year revenue guidance to $28 million – $33 million, up from $25 million – $30 million.
OmniAb, Inc. Warrant 2022- on Omniab Inc Financial Disclosures & SEC Filings
This article provides a comprehensive listing of OmniAb, Inc.'s financial disclosures and SEC filings, including quarterly and annual earnings reports, 8-Ks, 10-Qs, and 10-Ks. It details corporate events, investor updates, and press releases, offering insights into the company's financial performance, program growth, technology launches, and future outlook from 2021 through Q1 FY2026.
OmniAb, Inc. Financial Disclosures & SEC Filings
This article provides a comprehensive list of OmniAb, Inc.'s financial disclosures and SEC filings, including earnings reports (Forms 10-K, 10-Q, 8-K), corporate presentations, and investor updates stretching from Q1 2026 back to Q4 2021. It details key highlights for each filing, such as revenue growth, clinical progress, partner growth, program numbers, new technology launches like OmniUltra, and financial results. These documents offer insights into the company's financial performance, operational updates, and strategic outlook.
OmniAb, Inc. Warrant 2022- on Omniab Inc Financial Disclosures & SEC Filings
This article provides a comprehensive list of OmniAb, Inc.'s financial disclosures and SEC filings, including earnings reports, annual and quarterly reports, corporate presentations, and investor updates dating back to 2021. It highlights key business developments, financial performance metrics, and technological advancements mentioned within these documents, such as revenue growth, program expansion, new technology launches, and strategic partnerships. The information is intended for investors to evaluate the company's financial health and operational progress.
OmniAb, Inc.(NasdaqGM: OABI) dropped from Russell 2500 Growth Benchmark
OmniAb, Inc. (NasdaqGM: OABI) has been dropped from the Russell 2500 Growth Benchmark, a decision officially published on June 29, 2026. This exclusion is part of a broader removal from several Russell benchmarks, including the Russell Microcap Growth, Russell 2000 Growth, Russell 3000E Growth, Russell 3000 Growth, and Russell Small Cap Comp Growth benchmarks. The company specializes in licensing discovery research technology to pharmaceutical and biotech companies, focusing on identifying optimal antibodies and target-binding proteins.
Earnings Preview: OmniAb to Report Financial Results Post-market on May 07
OmniAb is scheduled to report its financial results after market close on May 07. This earnings preview indicates that investors and analysts will be closely watching the company's performance. The results will provide insight into the company's financial health and future outlook.
OmniAb, Inc.(NasdaqGM: OABI) dropped from Russell 2000 Growth Benchmark
OmniAb, Inc. (NasdaqGM: OABI) has been removed from the Russell 2000 Growth Benchmark. This news follows earlier reports of its removal from the Russell Microcap Growth Benchmark Index and the Russell 3000E Growth Benchmark. OmniAb specializes in licensing discovery research technology for therapeutic development, utilizing proprietary transgenic animals to create optimized antibody candidates.
OmniAb, Inc.(NasdaqGM: OABI) dropped from Russell 3000 Growth Benchmark
OmniAb, Inc. (NasdaqGM: OABI) has been dropped from the Russell 3000 Growth Benchmark. This move follows a series of similar announcements where the company was removed from other Russell indices, including the Russell 2500, Microcap, 2000, 3000E Growth, and Small Cap Comp Growth Benchmarks, all on June 29th (or June 28th for some). OmniAb specializes in licensing discovery research technology for therapeutic development, utilizing proprietary transgenic animals to create optimized antibody candidates.
OABI Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for OmniAb, Inc. (OABI) stock, including analyst opinions, historical price performance, and financial metrics. It highlights key data such as the current stock price, market capitalization, earnings reports, and volatility, while clarifying that the content is not investment advice.
Price to book forward of OmniAb, Inc. – BOATS:OABIW
This page provides financial information for OmniAb, Inc. (OABIW), specifically focusing on its price to book forward ratio. The data is presented through TradingView, noting that the market is currently closed with no trades.
OmniAb, Inc. Actuals & Estimates (NASDAQ:OABI)
This article provides an overview of OmniAb, Inc. (NASDAQ: OABI) stock performance, financial actuals, and analyst estimates. It covers various metrics including current stock price, market capitalization, earnings, revenue, and future forecasts, offering insights into the company's financial health and market position.
Price to earnings forward of OmniAb, Inc. – BOATS:OABIW
This article provides financial information for OmniAb, Inc. under the ticker symbol OABIW on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the "Price to earnings forward" metric. The content appears to be a financial data page from TradingView, showing market status and financial figures.
OmniAb Inc (OABI) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of OmniAb Inc (OABI), detailing its price momentum score of 8.80 in the Biotechnology & Medical Research industry, trading between resistance at $2.87 and support at $2.08. It evaluates various technical indicators like MACD, RSI, and moving averages, concluding with a "Buy" signal based on MA5 to MA200 and a mixed signal from other indicators. The analysis is presented as a reference for investors but warns that past performance is not indicative of future results.
OmniAb shareholders elect directors and ratify auditor at annual meeting By Investing.com
OmniAb, Inc. (NASDAQ:OABI) held its 2026 Annual Meeting where shareholders elected Jennifer Cochran, Ph.D., and Matthew W. Foehr as Class I directors for three-year terms. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Despite remaining unprofitable, OmniAb reported a significant Q1 2026 revenue increase of 242.9%, reaching $14.4 million, driven by advancements in partner programs and new agreements.
OmniAb (OABI) director Bertozzi exercises RSUs and receives new option, RSU grants
OmniAb director Carolyn R. Bertozzi exercised 20,000 Restricted Stock Units (RSUs) into common stock, increasing her direct holdings to 113,308 shares. She also received grants of 40,000 stock options at an exercise price of $2.03 and 20,000 new RSUs. Both the new RSUs and stock options are set to vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant date.
OmniAb (OABI) 2026 annual meeting elects directors and ratifies auditor
OmniAb, Inc. (OABI) held its 2026 Annual Meeting of Shareholders on June 17, 2026. During the meeting, shareholders elected Jennifer Cochran, Ph.D. and Matthew W. Foehr as Class I directors for three-year terms. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
OmniAb (OABI) director adds options and RSUs in Form 4 filing
OmniAb, Inc. director John L. Higgins reported compensation-related equity activity on June 17, 2026, as detailed in a Form 4 filing. He exercised 20,000 Restricted Stock Units (RSUs) into common stock, increasing his direct holdings to 2,962,320 shares. Additionally, Higgins received a grant of 40,000 stock options with an exercise price of $2.03 and 20,000 new RSUs.
OmniAb (OABI) director gains stock, options and RSUs in Form 4
OmniAb, Inc. director Steven Love reported equity compensation transactions and an option-related share acquisition according to a recent Form 4 filing. On June 17, 2026, he acquired 20,000 shares of Common Stock and received grants of 40,000 Stock Options and 20,000 Restricted Stock Units. These transactions indicate equity compensation and vesting events, not open-market purchases or sales, bringing his direct Common Stock holdings to 91,666 shares.
OmniAb (OABI) director receives options and RSUs, exercises 20,000 shares
OmniAb, Inc. director Steven C. Crouse reported equity compensation transactions, including exercising derivative rights to acquire 20,000 shares of Common Stock, increasing his direct holdings to 33,333 shares. He also received 40,000 stock options with a $2.03 exercise price and 20,000 Restricted Stock Units, both of which vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant. The filing indicates no share sales, focusing solely on acquisitions related to compensation.
OmniAb (OABI) director adds shares through RSU vesting and new equity grants
OmniAb director Jennifer R. Cochran reported equity transactions, including the vesting of 20,000 Restricted Stock Units (RSUs) into common stock, increasing her direct holdings to 185,274 shares. She also received a grant of 40,000 stock options with a $2.03 exercise price and 20,000 new RSUs, all subject to future vesting conditions. These transactions, detailed in a Form 4 SEC filing, highlight an increase in the director's equity stake in the company.
OmniAb (OABI) director granted stock options and RSUs
OmniAb director Philip J. Gotwals reported equity compensation, acquiring 20,000 shares of Common Stock from vested Restricted Stock Units, increasing his direct holdings to 33,333 shares. He also received 40,000 new stock options with a $2.03 exercise price and 20,000 new RSUs. These new awards will vest in full on the earlier of the next annual stockholder meeting or the first anniversary of their grant dates.
OmniAb Inc (OABIW) Institutional Confidence
This article provides details on the institutional confidence of OmniAb Inc (OABIW), listing significant institutional shareholders and changes in their holdings. Key shareholders include Walleye Capital LLC, Avista Capital Holdings, LP, and Wolverine Asset Management, LLC, with some showing 100% decreases and others significant increases or no change. The report is part of a broader company analysis by TradingKey, focusing on institutional activity.
OmniAb Inc (OABI) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of OmniAb Inc (OABI), showing its current valuation score is 7.35, ranking 247 out of 388 in its industry. The P/E ratio stands at -4.43, indicating a significant deviation from both recent highs and lows. Important valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Why Is OmniAb Gaining Attention In The Biotechnology Landscape?
OmniAb is gaining attention in the biotechnology sector due to its innovative antibody discovery technologies and research platforms. The company actively engages in scientific innovation and collaborations to support pharmaceutical and biotechnology development programs. These platforms are crucial for identifying and developing therapeutic antibody candidates for various medical conditions.
OmniAb Inc (OABI) Institutional Confidence
OmniAb Inc (OABI) has an institutional shareholding score of 5.00, placing it 133rd out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 3.41% quarter-over-quarter, reaching 57.16%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 3.27% of outstanding shares.
OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for OmniAb Inc (OABI), highlighting its current earnings forecast score of 8.57 within the Biotechnology & Medical Research industry. Analysts project an average price target of $8.00 with a strong buy rating based on 7 analysts. The report also includes expected revenue and EPS for upcoming quarters, as well as peer comparison data.
OmniAb Inc (OABIW) Financial Health: Profitability & Balance Sheet Analysis
This article from TradingKey provides a financial health analysis for OmniAb Inc (OABIW), focusing on its profitability and balance sheet. However, the analysis notes that relevant financial data has not yet been disclosed by the company, making a detailed assessment impossible at this time. The various financial health dimensions like cash and cash equivalents, total assets, and operational efficiency are listed but remain without specific data.
OmniAb Inc (OABI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for OmniAb Inc (OABI), categorizing its income by business segments for the fiscal year 2025. The primary revenue streams include service revenue, license and milestone revenue, royalty revenue, and xPloration revenue. The report highlights the proportion each segment contributes to the total revenue.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
This article lists several health care stocks that experienced significant movement during Wednesday's pre-market session. It details both gainers, such as Silexion Therapeutics and Jupiter Neurosciences, and losers, including Annovis Bio and Virax Biolabs Group, along with their respective stock changes, market caps, and recent earnings report dates.
OmniAb, Inc. Common Stock (OABI) Stock Price Today & Analysis
This article provides an analysis of OmniAb, Inc. (OABI) stock, including its current price, fundamental financials, and corporate information. It details how to buy OABI stock on the Gotrade app, explains that OABI does not currently pay dividends, and offers guidance on evaluating if the stock is expensive or cheap. OmniAb Inc. licenses discovery research technology for next-generation therapeutics, utilizing its OmniAb platform and "Biological Intelligence" to create optimized antibody candidates.
OmniAb, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-05-11
OmniAb, Inc. (NASDAQ:OABI) released its Q1 2026 earnings, reporting an EPS of -$0.06, which beat estimates by $0.04. The company's revenue reached $14.43 million, significantly surpassing expectations by $8.83 million and representing a substantial 247.30% year-over-year increase. This article presents the slide deck from their Q1 earnings call.
We're Hopeful That OmniAb (NASDAQ:OABI) Will Use Its Cash Wisely
This article analyzes OmniAb's (NASDAQ:OABI) cash position and burn rate, highlighting the importance of wise cash utilization for growth companies that are not yet profitable. The company currently holds $165.7 million in cash and short-term investments, with a burn rate suggesting it could fund operations for approximately 2.9 years. The article emphasizes that while OmniAb's cash runway appears adequate, investor confidence will depend on how effectively this capital is deployed to achieve future profitability.
Number of shareholders of OmniAb, Inc. – NASDAQ:OABIW
This article provides financial information for OmniAb, Inc. (NASDAQ: OABIW), focusing on its number of shareholders. It appears to be a stub or data-focused page from TradingView, presenting a barebones overview with copyright and product information. The core content is the heading "Number of shareholders of OmniAb, Inc." followed by "Period Value Change Change %," suggesting that the actual data points would be displayed below this structure.
OmniAb (OABI) FY 2025 Loss Of US$64.8m Keeps Profitability Narrative Under Pressure
OmniAb (OABI) reported a FY 2025 net loss of US$64.8 million, with a fourth-quarter revenue of US$8.4 million and a basic EPS loss of US$0.11. The company's profitability is under scrutiny, with sustained losses and forecasts predicting unprofitability for at least the next three years, leading to concerns about potential shareholder dilution, despite a forecasted 30.8% annual revenue growth and a strong partner ecosystem. The stock trades at a high P/S ratio of 11.4x, significantly above its DCF fair value of US$5.21 and analyst target of US$7.33, creating a valuation tension between growth potential and ongoing losses.
OmniAb, Inc. (NASDAQ:OABI) Q1 2026 Earnings Call Transcript
OmniAb, Inc. (NASDAQ: OABI) reported strong Q1 2026 results, beating earnings expectations with a reported EPS of $-0.06 against an expected $-0.1. The company saw a significant increase in revenue, primarily driven by milestone achievements from partner programs advancing in clinical stages. OmniAb also highlighted its innovative technologies like OmniUltra and OmnidAb, which are attracting new partners and expanding its market reach, leading to a revised and increased full-year revenue outlook.
OmniAb, Inc. (OABI) reports Q1 loss, tops revenue estimates
OmniAb, Inc. (OABI) reported a diluted loss per share of $0.06 for Q1, which was narrower than the Zacks Consensus Estimate of a $0.09 loss. The company also exceeded revenue expectations, posting $27.9 million compared to the consensus estimate of $27.01 million. Despite a year-over-year revenue decline, these results indicate a stronger-than-anticipated financial performance for the quarter.
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Announces Target Price $7
Craig-Hallum analyst Matt Hewitt has reiterated a "buy" rating for OmniAb (OABI.US) and set a target price of $7. According to TipRanks data, the analyst has a 38.4% success rate and an average return of -4.3% over the past year. This information is provided for informational purposes and is not an investment recommendation.
OmniAb, Inc. (OABI) reports Q1 loss, tops revenue estimates
OmniAb, Inc. (OABI) reported a first-quarter loss that was wider than anticipated, but its revenue surpassed Wall Street expectations. The company posted a loss of 12 cents per share on revenue of $29.7 million, exceeding analyst forecasts of an 8-cent loss and $28.3 million in revenue.
OmniAb’s Q1 2026 Revenue Rises to $25.3 Million, Net Loss Decreases
OmniAb reported a significant financial improvement in Q1 2026, with revenue increasing by 15% to $25.3 million from $22 million in Q1 2025. Concurrently, the company's net loss decreased to $12.9 million, a substantial improvement from the $20.1 million loss in the prior year's first quarter. These results highlight OmniAb's operational growth and progress.
OmniAb Q1 Earnings Call Highlights
OmniAb (OABI) reported strong Q1 2026 results, driven by progress in its partner pipeline, leading to increased milestone revenue. The company highlighted advancements in clinical programs, including several proprietary technologies entering later-stage development, as well as new technology innovations like OmniUltra. Financial results showed a significant increase in revenue and a narrower net loss year-over-year, leading OmniAb to raise its full-year 2026 revenue guidance.
OmniAb (OABI) Q1 2026 Earnings Transcript
OmniAb (OABI) reported a strong Q1 2026, with total revenue reaching $14.4 million, significantly up from $4.2 million, primarily due to increased milestone revenue from partner clinical program advancements. The company raised its full-year 2026 revenue guidance to $28 million to $33 million, driven by an unanticipated partner milestone, while maintaining unchanged cash operating expense guidance at $50 million to $55 million. OmniAb highlighted the traction of its novel technologies, OmniUltra and OmnidAb, and the growing interest in its xPloration platform, alongside a robust pipeline of over 400 active programs and 32 clinical programs.
OmniAb Q1 Earnings Call Highlights
OmniAb (NASDAQ: OABI) reported a strong first quarter for 2026, driven by significant progress in its partner pipeline and associated milestone revenues. The company ended the quarter with 32 active clinical programs, saw two OmniAb-derived programs enter Phase I human testing, and highlighted several advancements, including an antibody moving from Phase I to Phase III development for multiple myeloma. OmniAb also emphasized its innovative technology, including the newly launched OmniUltra platform, and raised its full-year 2026 revenue outlook to $28 million to $33 million based on Q1 performance.
TD Cowen Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $3
TD Cowen has reiterated its Buy rating on OmniAb (OABI.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.
OmniAb (OABI) Q1 2026 revenue surges 247% while net loss shrinks
OmniAb (OABI) reported a significant increase in Q1 2026 revenue, surging 247% to $14.4 million, primarily driven by a $10.0 million increase in license and milestone revenue. While the company remains unprofitable, its net loss narrowed substantially to $7.7 million from $18.2 million in Q1 2025 due to revenue growth and lower operating expenses. OmniAb continues to expand its antibody discovery platform, boasting 107 active partners and 409 active programs, with sufficient cash reserves to fund operations for at least the next 12 months.
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. reported strong first-quarter 2026 financial results, with a significant increase in revenue to $14.4 million and a reduced net loss of $7.7 million. The company raised its full-year 2026 revenue guidance to between $28 million and $33 million, driven by multiple partnered programs advancing into later-stage clinical development, including IMVT-1402 and TEV-'408. OmniAb continues to expand its technology platform with initiatives like OmniUltra™ and its xPloration® partner access program.
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. reported strong first-quarter 2026 financial results, with revenue significantly increasing to $14.4 million compared to $4.2 million in the prior year, primarily driven by milestone revenue. The company also raised its 2026 financial guidance, anticipating revenue between $28 million and $33 million, and highlighted advances in multiple partner programs into later-stage clinical development, underscoring the value of its technology platform. Key business highlights included progress in IMVT-1402, batoclimab, TEV-'408, and precemtabart tocentecan programs.
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook
OmniAb projects its 2026 revenue to be between $28 million and $33 million, driven by anticipated partner milestones. This forecast indicates a significant increase from previous expectations, reflecting strong performance and successful progression of its collaborations. The company's outlook is bolstered by the potential for additional payments tied to the advancement of therapies developed using its technology.
Earnings call transcript: OmniAb Q1 2026 sees revenue surge, stock climbs
OmniAb, Inc. reported a significant 242.9% year-over-year revenue increase to $14.4 million in Q1 2026, leading to a 2.8% stock climb. Despite an InvestingPro analysis suggesting overvaluation, the company improved its net loss significantly and raised its full-year revenue outlook, driven by advancements in partner programs and new technology platforms. The earnings call highlighted the strength of its technology, partner ecosystem, and pipeline, with expectations for continued growth and clinical advancements.
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) reported a Q1 loss of $0.06 per share, outperforming the Zacks Consensus Estimate of a $0.1 loss, and exceeded revenue estimates with $14.43 million for the quarter ended March 2026. Despite underperforming the market year-to-date, the company holds a favorable Zacks Rank #2 (Buy) due to positive earnings estimate revisions, suggesting potential for future market outperformance. The article also touches on Plus Therapeutics (PSTV) as another stock in the Medical-Drugs industry, which is yet to report Q1 results.
